Interim net sales increased by 800 million yen from the previous forecast, operating income increased by 900 million yen, ordinary income increased by 800 million yen, and interim net income increased by 500 million yen. Net sales are 32,300 million yen and profits have been revised upward. The full-year forecast is currently under review and will be announced on November 11 along with the Q2 financial results.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4538","jir_company_name":"Fuso Pharmaceutical Industries,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4538-20261104-01.pdf","jir_short_summary":"Interim net sales increased by 800 million yen from the previous forecast, operating income increased by 900 million yen, ordinary income increased by 800 million yen, and interim net income increased by 500 million yen. Net sales are 32,300 million yen and profits have been revised upward. The full-year forecast is currently under review and will be announced on November 11 along with the Q2 financial results.","jir_summary":"### Overview of Revision to Earnings Guidance\nFuso Pharmaceutical Industries,Ltd. has revised upward its earnings guidance for the second quarter of the fiscal year ending March 2027. Net sales are expected to exceed the previous forecast, reaching 32,300 million yen; operating income is projected at 1,700 million yen; ordinary income at 1,400 million yen; and interim net income at 1,000 million yen. Interim net income per share is 117.15 yen, an improvement from the prior forecast. Reasons for the revision include that, although there was a negative impact from drug price revisions, sales remained firm due to the effectiveness of promotional activities, and some cost increases were deferred to the second half. The full-year forecast is currently under review and will be announced on November 11.\n\n### Full-Year Outlook and Points to Note\nFactors contributing to the interim upside include the containment of some expected increases in raw material costs and the impact of new licensing agreements. The full-year earnings forecast is under review and will be announced at the Q2 results presentation on November 11. Depending on future market trends, foreign exchange movements, and raw material trends, there remains a risk of further revisions.","jir_financial_highlights":"Net Sales: 32,300 million yen (vs. previous forecast +800 million yen)\nOperating Income: 1,700 million yen (vs. previous forecast +900 million yen)\nOrdinary Income: 1,400 million yen (vs. previous forecast +800 million yen)\nInterim Net Income: 1,000 million yen (vs. previous forecast +500 million yen)\nInterim Net Income per Share: 117.15 yen (vs. previous forecast +58.59 yen)","jir_category":"","jir_hashtags":"#FusoPharmaceuticalIndustries, #EarningsGuidanceRevision","jir_key_figures":"Net Sales: 32,300 million yen\nOperating Income: 1,700 million yen\nOrdinary Income: 1,400 million yen","jir_meta_title":"[Fuso Pharmaceutical Industries,Ltd.] Upward Revision to Earnings Guidance\uff5cQ2 FY2027","jir_meta_description":"Fuso Pharmaceutical Industries,Ltd. has revised upward its Q2 FY2027 earnings guidance: net sales 32,300 million yen, operating income 1,700 million yen, ordinary income 1,400 million yen, interim net income 1,000 million yen, EPS 117.15 yen. Full-year forecast to be announced on November 11.","jir_og_title":"Fuso Pharmaceutical Industries,Ltd. Revises Earnings Guidance\uff5cQ2 FY2027","jir_og_description":"Fuso Pharmaceutical Industries,Ltd. has revised up its interim earnings guidance. Net sales 32,300 million yen; profits also revised upward. Full-year outlook to be announced on November 11.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57749,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-141151","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n